Boehringer Ingelheim: Osteoarthritis trials
The registry lists 15 Osteoarthritis studies with Boehringer Ingelheim as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 2Phase 3 2Phase 4 3No phase 8(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the KneeCompletedNCT02126826Phase 1Results posted
- Assessing the Impact of MOVALIS in Osteoarthritis and Rheumatoid Arthritis Patients on Health Related Quality of LifeCompletedNCT00619177Results posted
- Effectiveness and Safety of Synvisc® Versus Usual Treatments in Patients With Knee OsteoarthritisCompletedNCT02197026Phase 4
- Retrospective Follow-up Study of Synvisc® in Patients With Knee OsteoarthritisCompletedNCT02195557
- Use of Synvisc® in Knee Osteoarthritis - Survey on PracticeCompletedNCT02195544
- Use of Synvisc® in Knee Osteoarthritis - Medico-economical StudyCompletedNCT02195505
- Retrospective Follow-up of Synvisc® in Active Patients With Knee OsteoarthritisCompletedNCT02195492
- Efficacy and Safety of Meloxicam (Mobicox®) in Mexican Population With Rheumatic DiseasesCompletedNCT02184039
- Study to Assess the Efficacy and Safety of Meloxicam vs. Diclofenac SR in Patients With Osteoarthritis of the KneeCompletedNCT02183129Phase 4
- A Study to Access the Efficacy and Safety of Meloxicam in Patients With Osteoarthritis of the KneeCompletedNCT02183116Phase 4
- Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With OsteoarthritisCompletedNCT02183064Phase 3
- Postmarketing Surveillance Study With MOBEC®CompletedNCT02182726
- Safety, Tolerability, Pharmacokinetics and -Dynamics of Multiple Rising Oral Doses of BI 113823 in Patients Patients With Osteoarthritis of the KneeTerminatedNCT01207973Phase 1
- Safety and Efficacy of Mobic Inj. (Meloxicam) for the Patients With OA or RA: Observational StudyCompletedNCT00612885
- A Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With OsteoarthritisCompletedNCT00239395Phase 3